Article Correctness Is Author's Responsibility: Addition of Immunotherapy to Standard Treatment for Advanced Stage Non-Small Cell Lung Cancer is Safe and Tolerable as First-Line Therapy

Newswise imageResearch from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).